Novo Nordisk announced that the highly popular drug could have expanded FDA approval in six months. Novo Nordisk recently announced that its headline-making weight loss drug Wegovy could receive expanded US Food and Drug Administration (FDA) approval within six months, opening the door to much more readily available coverage by health insurance plans. The drug is already highly sought-after, but is not necessarily covered by most policies. Novo Nordisk’s chief financial officer Karsten Munk Knudsen said that the company’s application for approval of Wegovy as a cardiovascular disease reduction medication…
Read MoreHealth insurance could soon cover weight loss drug Wegovy
